Survodutide sodium

The EC₅₀ is 0.36 nM for Survodutide (BI 456906) sodium in the endogenous mouse GLP-1R in the insulinoma cell line MIN6, and the EC₅₀ is 60 pM for GLP-1. In 0.5% human and mouse plasma, Survodutide sodium shows a similar potency to that of endogenous GLP-1. For the GCGR, in 0.5% human and mouse plasma, Survodutide sodium is 6-fold less potent (0.29 and 0.17 nM, respectively) in relation to endogenous glucagon (47 and 30 pM, respectively)^[1].
Proteolytic stability of Survodutide sodium is helped by C-terminal amidation and the introduction of a non-coded amino acid 1-aminocyclobutane-1-carboxylic acid (Ac4c) in position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4. The desired extended terminal half-life of Survodutide sodium is achieved by the introduction of a glycine-serine linker in position 24, carrying a C18 di-acid^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.